Xenetic Biosciences shares surge 11.11% intraday on progress toward Phase 1 trials for DNase I pancreatic cancer therapy and improved 2025 financials.

Xenetic Biosciences surged 11.11% intraday following the release of its full-year 2025 financial results and updates on clinical progress. The company highlighted encouraging preclinical and translational data for its DNase-based technology targeting neutrophil extracellular traps (NETs) in cancers, including pancreatic carcinoma and lymphoma. It also reported $7.9 million in cash reserves post-October 2025 funding and advanced IND-enabling activities for its DNase I program. These developments, coupled with strategic collaborations (e.g., Scripps Research) and expanded investigator-initiated trials, signaled progress toward Phase 1 clinical trials. The bullish news aligned with the stock's sharp intraday rise, reflecting investor optimism about the company's pipeline and capital discipline.